Educational content about cannabinoid science, not medical advice. Consult a healthcare professional before combining CBD products with medication. Our age policy
Entourage Effect: What 1998 Recorded, What Stays Open
Definition
The entourage effect is the idea that compounds occurring together behave differently from the same compounds taken alone. The phrase was coined in 1998 for a specific laboratory observation involving molecules the body makes itself, and was later applied to hemp cannabinoids and aromatic compounds. It remains a hypothesis with a plausible mechanism, not a demonstrated human result.
1998: one word, two molecules
| Point | What the 1998 work records [1] | What it does not cover |
|---|---|---|
| The word | 1998 is the year the phrase entered the scientific literature, in work by Ben-Shabat and colleagues on endogenous fatty acid glycerol esters and their effect on 2-arachidonoyl-glycerol [1]. | A name given to a laboratory observation. Not a claim about plants, extracts or people. |
| The active molecule | 2-arachidonoyl-glycerol, usually written 2-AG. It is an endogenous signalling molecule, one the body produces itself, and one of the two best described endocannabinoids alongside anandamide [1]. | Not a plant compound, and not something anyone takes from a bottle. |
| The companion compounds | A group of endogenous fatty acid glycerol esters, structurally similar to 2-AG. Measured on their own, they showed no cannabinoid activity at all [1]. | Inactive means inactive in that test system, at those concentrations. |
| The observation | With those inactive esters present, the cannabinoid activity of 2-AG came out enhanced. Molecules without measurable activity of their own changed what the active molecule did in the same system [1]. | One system. One readout. One pair of molecule types. |
| How the body handles these molecules | Anandamide and 2-AG are made on demand rather than stored, then broken down quickly by dedicated enzymes: fatty acid amide hydrolase and monoacylglycerol lipase. | The enzymes are named in the literature. Rates in a living person are a separate question. |
| The proposed mechanism | Structurally similar molecules sitting in one mixture compete for the same handling and breakdown pathways. The 1998 interpretation reads plainly: with companion esters occupying those routes, the active molecule stays available longer [1]. | A mechanism on paper, supported by biochemistry rather than by a measured outcome in humans. |
| Level of evidence | Laboratory biochemistry. Specific molecules, specific concentrations [1]. | No clinical arm, no participants, no dosing. |
| Two details that tend to fall away | First, the term was coined for molecules the body makes itself. Second, it described one named interaction, not mixtures in general [1]. | Both details matter as soon as the phrase leaves the paper and lands on a label. |
The 2011 formulation, in pieces
| Element | What is on the record | Status |
|---|---|---|
| The paper most people mean | The best known modern version of the idea is Russo's 2011 review, which proposed synergy between phytocannabinoids and terpenoids [2]. | A proposal set out in a review article. Cited constantly, which is not the same as tested. |
| Phytocannabinoids | Cannabinoids that come from the plant, as distinct from the endogenous ones named in the 1998 work [1]. | A class of compounds, measurable in a batch analysis. |
| Terpenoids | The aromatic compounds behind the smell, the reason one variety does not smell like the next [2]. | Named as a class. What each individual compound contributes is its own question. |
| What synergy means here | Compounds together doing something that neither shows on its own. That is the shape of the 1998 result, carried across to plant compounds [1][2]. | Borrowed shape, different objects. |
| How the proposal breaks down | The argument separates into roughly four claims, and each one can be examined on its own rather than accepted as a package [2]. | Useful for readers: you can agree with one part and reserve judgement on the rest. |
| Claim one | Composition varies from plant to plant, and that variation is relevant [2]. | The most approachable of the claims, because composition is something a laboratory can quantify. |
| 1998 next to 2011 | Different subjects entirely. 1998: endogenous esters acting on 2-AG in a test system [1]. 2011: plant cannabinoids alongside plant aromatics [2]. | Two papers, one phrase. Keeping them apart is most of the clarity available here. |
| Where the idea sits | Influential, widely quoted, and built on a mechanism that makes biochemical sense [1][2]. Human evidence remains incomplete. | Hypothesis. Not a finding you can pin to a person. |
What the coinage actually named
Two words did a lot of travelling. The 1998 finding has a narrow, precise shape: molecules with no measurable activity of their own altered the activity of an active molecule inside the same system [1]. Worth reading twice, because that sentence is the entire foundation of the term. Nothing in it involves a plant. Nothing in it involves a bottle.
The coinage had a target. It described endogenous fatty acid glycerol esters acting on 2-AG, and it was published as a piece of biochemistry, with named molecules at stated concentrations [1]. Read the phrase instead as a general rule, that any mixture of plant compounds outperforms any single compound, and you have gone well past the data the word was built on [1].
Russo's 2011 review did something different, and did it openly. It took the shape of the 1998 observation and proposed it for plant compounds, phytocannabinoids together with terpenoids [2]. That is a reasonable move to make in a review. It is still a proposal. The mechanism from 1998 stays plausible either way: similar molecules competing for the same breakdown pathways is ordinary biochemistry, not an exotic claim [1].
Beyond hemp, the same signalling system
The framework was never cannabis-specific [1]. Russo's 2016 review widened the discussion past cannabis altogether, to other plants whose constituents interact with the endocannabinoid system [3]. That matters for how the idea should be read. If comparable interactions show up across different botanical sources, then cannabis is one case of a broader pattern rather than a special exception [3]. Hemp becomes an example, not the point. It also makes the marketing version of the phrase harder to sustain, because a general botanical pattern is not an argument for one particular plant, one particular extract, or one particular bottle.
Three arms, one honest description
Three arms. That is the short version of what a study able to settle this would need. The hypothesis is falsifiable, which is the encouraging part: you can state in advance which result would count against it [2]. The comparison has to be matched. A purified compound on its own. A reconstituted mixture, assembled from named compounds. A whole extract. And the same quantity of the study compound in every arm, because otherwise a difference in amount is doing the work and nobody can tell.
Until studies of that kind exist, here is the accurate description, and we would rather write it than something warmer: a hypothesis with a plausible mechanism, originating in the 1998 literature, given its influential formulation in 2011, with human evidence still incomplete [1][2]. Working with cannabinoids since 2014 has taught us that the phrase does more work on labels than in journals.
- Matched arms, equal quantities: purified compound, reconstituted mixture, whole extract, with the same amount of the study compound in each [2].
- A prediction stated before the data arrive, so the result can go either way. That is what falsifiable means in practice [2].
- Human data, since the 1998 work was biochemistry and the 2011 paper was a review proposing a direction [1][2].
- Reporting that keeps 1998 and 2011 apart, because the two papers examined different molecules and answered different questions [1][3].
- Composition first, one claim at a time: variation between plants is measurable, and it is the first of the four claims rather than proof of the last [2].
- A full-spectrum extract, meaning one that keeps the plant's broader cannabinoid and terpenoid profile, is a composition statement. A batch report tells you what is in the bottle, not what the mixture does.
- Wording that matches the evidence: hypothesis, mechanism, open question. Not demonstrated, not proven.
Frequently Asked Questions
4 questionsWhich molecules was the 1998 paper actually about?
What are terpenoids?
Does the idea apply only to cannabis?
How should the entourage effect be described right now?
About this article
Luke Sholl has been writing about cannabinoids, CBD, and the broader benefits of nature since 2011. His background includes first-hand cannabis cultivation experience spanning the full seed-to-harvest lifecycle across so
This wiki article was drafted with AI assistance and reviewed by Luke Sholl, CBD & wellness writer. Editorial oversight by Joshua Askew.
Medical disclaimer. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before use of any substance.
Last reviewed August 26, 2026
References (3)
- [1]Ben-Shabat et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. DOI: https://doi.org/10.1016/s0014-2999(98)00392-6
- [2]Russo (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. DOI: https://doi.org/10.1111/j.1476-5381.2011.01238.x
- [3]Russo (2016). Beyond Cannabis: plants and the endocannabinoid system. DOI: https://doi.org/10.1016/j.tips.2016.04.005
Related Articles
Does CBG Make You Sleepy? What's Actually on Record
The idea that cannabigerol brings on drowsiness is widely repeated, but the 2021 review by Nachnani and Barrett describes receptor sites rather than sensations in volunteers. The same thing happened to CBN, and Corroon traced it in 2021.
THCA vs THC: A Single Carboxyl Group Apart
One carboxyl group separates the acid form found in the plant from the neutral compound most people talk about. Here is what happens when it goes, and why two lab figures from one plant are not a contradiction.
Broad Spectrum CBD: What The Term Covers
Broad spectrum sits between full spectrum and isolate, and it's the one name on that list with no legal definition behind it. Here's what the term commits to, what research covers, and what our own range holds.
THCP: A Cannabinoid With Two Extra Carbons
Tetrahydrocannabiphorol turned up in an Italian medicinal cannabis variety in December 2019, in work led by Cinzia Citti [1]. Here is what that report actually records, and where our own range sits.
CBD Research: What the Human Data Covers
A calm look at what has actually been measured in cannabidiol studies, where the published record thins out, and what to check before you believe a claim.
Serotonin, 5-HT and the One Cannabinoid Link on Record
5-HT is not one receptor but at least seven families of them, each split into subtypes. Here is what that means for reading claims, and what the 2005 in vitro report on cannabidiol at 5-HT1a does and does not cover [1].
PEA and Anandamide: A Family Resemblance in Chemistry
Palmitoylethanolamide shares a chemical class and a clearance route with anandamide. Here is what that family resemblance settles, and what it deliberately leaves open.
The Endocannabinoid System in Six Papers, 1964 to 1995
The structure of THC was published in 1964, the first cannabinoid receptor in 1990, anandamide in 1992. Six reports, thirty-one years, and a name that runs backwards.
2016: What Clinical Endocannabinoid Deficiency (CECD) Actually Means
CECD is a testable idea about underactive endocannabinoid signalling, set out most clearly in a 2016 paper by Russo [1]. Here is what that paper names, and where the record stops.
